Latest News

 Filter by Provider

Intel's margins are rising, which could drive significant earnings growth.

Lexeo Therapeutics (NASDAQ:LXEO) outlined upcoming clinical and regulatory milestones for its gene therapy programs in Friedreich’s ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy during the Chardan Healthcare Conference. Chief Financial Officer Lou Tamayo said the clinical-

The S&P 500 might be vulnerable to a 20% bear market decline, given the growing number of risks.

Volatility is a recurring theme in this company's story line.

Planet Fitness shares have slumped amid slowing membership growth and AI-related concerns, but analysts see over 30% upside ahead of third-quarter earnings on Nov. 5.

An investment in these three stocks could more than triple in value by 2030.

There’s more to Social Security’s annual cost-of-living adjustment (COLA) than meets the eye.

This under-the-radar mining stock boasts a Superscore of 78 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

This under-the-radar gold mining stock boasts a Superscore of 75 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

This under-the-radar copper mining stock boasts a Superscore of 84 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

This under-the-radar gold mining stock boasts a Superscore of 81 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

This under-the-radar gold mining stock boasts a Superscore of 71 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

Veradermics' shares are up nearly 270% since its IPO earlier this year.

If equity markets tumble, the Vanguard Information Technology ETF should be on investors' shopping lists.

It's a red flag investors would rather not see waving, but most of them may not have put this shift in its proper perspective.

New defined outcome ETFs QBKV, SBAR, and XX offer varied buffer, income, and leveraged strategies tied to small caps, options income, and the S&P 500, each with distinct costs and risks.

It's up more than 1,000% over the past three years.

A stock split could boost Micron's stock price by lowering the price per share.

If history is any guide, pain at the pump should not result in pain for Bitcoin investors.

Men's average Social Security benefits exceed women's at every age, a gap rooted in earnings history and survivor-benefit implications.

This under-the-radar mining stock boasts a Superscore of 80 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

This electric air taxi stock is in recovery mode right now.

Opus Genetics (NASDAQ:IRD) outlined commercialization expectations for its newly approved presbyopia eye drop, progress across its inherited retinal disease gene therapy pipeline and its funding strategy during an investor panel featuring Chief Executive Officer Dr. George Magrath and Chief Financia

Monument Traders Alliance strategists detail a volatility-trading sleeve using IWM, QQQ and GLD options alongside longer-term holdings in Agnico Eagle Mines and Nuveen Municipal Value Fund for income.

The market has crashed before, and it'll probably happen again. So it's best to have a plan ready.

Tilray's transformation is still ongoing, but it just reached a critical milestone.

Musk just provided a mind-boggling 2027 revenue forecast for Space Exploration Technologies.

Netflix wants to claw back market share from YouTube, which has made considerable gains.

The earnings report and call were short on razzmatazz but long on substance, strengthening the investment case for the stock.

Neurocrine's expanding drug portfolio could drive substantial growth through 2031.

Deep Fission (NASDAQ:FISN) outlined its development, regulatory and financing plans for underground nuclear power projects during its October 2026 business update, targeting initial commercial power from a pilot project in Parsons, Kansas, by December 2027 and broader deployments beginning in 2028.

The company's third quarter was marked by double-digit growth.

Forecasts point to a high likelihood of continued gains, but possible headwinds could interrupt growth.

If things seem too perfect on Wall Street, they probably are.

For its stock to take off, Samsara must transform customer value into profitable growth.

The conglomerate bought back its shares in June for around $488 each. Are they still a buy at a record?

You might be able to turn that $10,000 into $115,347 -- or more. (Or less.)

The power of dollars compounding over 20 years can turn a small dividend income into a huge one.

Investing in just this one exchange-traded fund (ETF) for the past 25 years could have set you up for serious financial security.

The stock has been on a great run this year.

Adagene (NASDAQ:ADAG) is advancing its masked anti-CTLA-4 antibody, ADG126, also known as muzastotug, in metastatic microsatellite-stable colorectal cancer (MSS CRC) and in a neoadjuvant investigator-sponsored trial in Singapore, Chief Strategy Officer Mickael Chane-Du said during a Chardan conferen

Bloom Energy has benefited from tailwinds from data centers for power solutions. Here's what the company must do to continue delivering for investors.

Exceeding expectations on the bottom line can't compensate for this shortcoming -- at least in some investors' eyes.

Many AI stocks beat the Nasdaq Composite this year, and these three picks look like they can repeat the feat in 2027.

Earnings jumped 22% last fiscal year. Why would I still want the stock around 12% cheaper?

These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

Annaly and AGNC are getting hit by rising rates; is that an opportunity for investors or a valid recognition of risk?

Just because you can multiply daily moves, doesn't mean you should.

The shocking part is that the gift is only a drop in the bucket compared to the founder's total wealth.

You don't have to wait until December to find out how much your Social Security check will grow.